Irritable Bowel Syndrome
Conditions
Interventions
Sponsors
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medicine Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) IBS patients: ? Meet the Rome III diagnostic criteria of IBS; ? Age 18-70; ? The course of disease is more than 6 months; (4) Lack of morphological changes and biochemical abnormalities that could explain symptoms; ? Did not use any medication for IBS at least 2 weeks before treatment (except emergency treatment); ? Did not receive acupuncture treatment for IBS or psychiatric treatment in the last 3 months, and did not donate blood or participate in clinical trials of other drugs; ? Voluntarily participate in the study and sign the informed consent. (2) Healthy subjects: ? Ask about their health status, and perform detailed physical examination (physical examination, electrocardiogram, liver and kidney function, routine hematuria and other laboratory tests) to prove that they are healthy; ? Regular work and rest, no smoking, drug, alcohol abuse history, no drug abuse history. ? Antibiotics were prohibited until the end of the study; ? During the test, the smoking ban, alcohol, tea, coffee and other stimulating drinks should be observed, and fermented dairy products such as yogurt should be prohibited.
Exclusion criteria
Exclusion criteria: ? Patients with alarm symptoms, such as abnormal findings in physical examination, fever, weight loss, blood in the stool, continuous severe abdominal pain lasting more than 12 h/d, acute abdominal pain, etc.; ? Systemic diseases affecting digestive tract function (such as gallbladder pancreatitis, hyperthyroidism, diabetes, chronic renal insufficiency, neurological diseases); (3) Patients with serious primary diseases such as cardiovascular system, liver, kidney, hematopoietic system, mental disease and obvious cognitive dysfunction; ? Have a history of abdominal or rectoanal surgery; ? Women during pregnancy, lactation and postpartum =12 months; ? Metal allergy or severe fear of needles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal sample metagenomic sequencing bacterial community structure species abundance;Low frequency fluctuation amplitude of resting state fMRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in metagenomic integration of metabolic networks in fecal samples;Resting state functional magnetic resonance imaging (FMRI) activates brain regions;Resting state functional magnetic resonance imaging (RS-FMRI) functional connection;The SAS Anxiety Scale;IBS-SSS;Local consistency of resting state fMRI; | — |
Countries
China
Contacts
Public ContactJia Liu
Outcome results
None listed